4 results about "Multikinase inhibitor" patented technology

The invention discloses a colorectal cancer treatment effect evaluation method, system and equipment based on SPP1 + TAMs. According to the application, the high heterogeneity of the TAM in the colorectal cancer and the metastatic microenvironment thereof is systematically revealed from three dimensions of spatial distribution, metabolic characteristics and functional states. On the basis, the invention provides a method for evaluating the treatment effect of the multi-kinase inhibitor and / or the anti-PD-1 therapy medicine on the colorectal cancer based on SPP1 + TAMs, a medicine screening method, a system, equipment and the like, so that a doctor is assisted in evaluating the treatment effect of a patient suffering from the colorectal cancer, and a clinician is guided to formulate an individualized treatment scheme for the patient; meanwhile, a new thought is provided for treatment of colorectal cancer.

Provided are compounds of Formula (I), a tautomer thereof, a deuterated derivative of the compound or the tautomer, and a pharmaceutically acceptable salt of the foregoing, compositions comprising the compounds of Formula (I), a tautomer thereof, a deuterated derivative of the compound or the tautomer, and / or a pharmaceutically acceptable salt of the foregoing, and methods of using the same, in treating, for example, the diseases, disorders, or conditions mediated by the inhibition of protein kinases, such as Hematopoietic progenitor kinase 1 (HPK1, MAP4K1), Human Fms-like tyrosine kinase 3 receptor (FLT3), and Aurora kinases.

To provide appropriate treatment for liver cancer patients, we offer indicators of sensitivity to multi-kinase inhibitors. [Solution] The present invention provides a testing method, testing apparatus, and testing program that use the fat content in liver cancer tissue as an indicator of sensitivity to multi-kinase inhibitors. This makes it possible to predict the therapeutic effect of multi-kinase inhibitors and provide appropriate treatment to individual liver cancer patients. The fat content can be calculated from images of liver cancer tissue or signals for image display. Images include MRI images, CT images, ultrasound images, stained images of tissue biopsies, etc. Signals for image display include MR signals, etc. Examples of multi-kinase inhibitors include lenvatinib and sorafenib.

Disclosed are compositions and methods for inducing pterygium regression from the visual axis / corneal center, stabilizing pterygium, treating hyperemia and symptoms in pterygium patients, and treating pterygium recurrence after pterygium resection. The method comprises administering a multi-kinase inhibitor, an antimetabolite, or a combination thereof to a patient requiring the method.